How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

911 results for

Acne Vulgaris Management

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris

A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris (Chromogenix) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02647528 Recruitment Status : Withdrawn (funding withdrawn) First

2015 Clinical Trials

142. Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris

Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris (Narciso) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02716090

2015 Clinical Trials

143. A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris

A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02595034 Recruitment Status : Completed First Posted : November 3, 2015 Last Update Posted : May 4, 2017 Sponsor: Taro

2015 Clinical Trials

144. Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris

Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Benzac 5% Gel (...) in Combination With Cosmetic Products in Acne Vulgaris (Benzac) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02589405 Recruitment Status : Completed First Posted : October 28, 2015 Results First Posted : February 11, 2019 Last Update Posted : February 11, 2019 Sponsor: Galderma Collaborator: Proinnovera

2015 Clinical Trials

145. Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02525822 Recruitment Status : Unknown Verified September 2015 by Valeant

2015 Clinical Trials

146. Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02556788 Recruitment Status : Completed First Posted : September 22, 2015 Last

2015 Clinical Trials

147. A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Thorough ECG (...) Study in Subjects With Acne Vulgaris Treated With SB204 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02581072 Recruitment Status : Completed First Posted : October 20, 2015 Last Update Posted : November 19, 2018 Sponsor: Novan, Inc. Collaborator: Spaulding Clinical Research LLC Information

2015 Clinical Trials

148. A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onextonâ„¢ Gel in the Treatment of Acne Vulgaris

A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onextonâ„¢ Gel in the Treatment of Acne Vulgaris A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02578043 Recruitment Status : Completed First Posted : October

2015 Clinical Trials

149. Efficacy and Tolerability of a Fixed Combination of Clindamycin Phosphate (1.2%) and Benzoyl Peroxide (3.75%) Aqueous Gel in Moderate or Severe Adolescent Acne Vulgaris Full Text available with Trip Pro

Efficacy and Tolerability of a Fixed Combination of Clindamycin Phosphate (1.2%) and Benzoyl Peroxide (3.75%) Aqueous Gel in Moderate or Severe Adolescent Acne Vulgaris Acne is commonplace in adolescents and can be difficult to manage. Providing an effective and well-tolerated treatment may lead to improved adherence, increased patient satisfaction, and improved clinical outcomes.A post hoc analysis of efficacy and cutaneous tolerability in 289 adolescents (age range, 12 to <18 years (...) ) with moderate-to-severe acne who had been enrolled in a multicenter study and were randomized to receive either clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel or vehicle once daily for 12 weeks.Significantly superior reductions in lesion counts were observed in the clindamycin phosphate 1.2%/benzoyl peroxide 3.75% gel group compared to vehicle from Week 4, with mean percent reductions in inflammatory and noninflammatory lesions from baseline of 59.9 percent and 50.5 percent, respectively (both P

2015 The Journal of clinical and aesthetic dermatology Controlled trial quality: uncertain

150. A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02491060 Recruitment Status : Unknown Verified September 2015 by Valeant

2015 Clinical Trials

151. British Association of Dermatologists guidelines for the management of pemphigus vulgaris

British Association of Dermatologists guidelines for the management of pemphigus vulgaris GUIDELINES BJD British Journal of Dermatology British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017* K.E. Harman, 1 D. Brown, 2 L.S. Exton, 3 R.W. Groves, 4 P.J. Hampton, 5 M.F. Mohd Mustapa, 3 J.F. Setter?eld 4,6 and P.D. Yesudian 7 1 University Hospitals Leicester, Leicester Royal In?rmary, In?rmary Square, Leicester, LE1 5WW, U.K. 2 St John’s Institute (...) accreditation is valid until 31 May 2021 and applies to guidance produced using the process described in updated guidance for writing a British Asso- ciation of Dermatologists clinical guidance – the adoption of the GRADE methodology 2016. The original accreditation term began on 12 May 2010. More information on accreditation can be viewed at www.nice.org.uk/accreditation. 1.0 Purpose and scope The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management

2017 British Association of Dermatologists

152. Impact of the M22-IPL Acne Filter on Acne Vulgaris

Impact of the M22-IPL Acne Filter on Acne Vulgaris Impact of the M22-IPL Acne Filter on Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Impact of the M22-IPL Acne Filter on Acne Vulgaris (...) Summary: Up to 20 healthy subjects age 15-45 years old ,Skin Phototype I-V,Study will be conducted in 1 site. Primary objectives is to evaluate the efficacy of IPL acne filter treatment for improvement of acne vulgaris as assessed by lesion count. Condition or disease Intervention/treatment Phase Acne Device: M22-IPL Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 13 participants Intervention Model: Single Group

2014 Clinical Trials

153. Management of acne

updated information on the patho­ genesis of acne, outlines methods for evaluating acne severity, provides evidence­ based guidance on treatments for acne vulgaris and recommends treatments for acne according to severity. To support clinical practice, recommenda­ tions are made for three categories of acne sever­ ity: comedonal acne, which consists of small white papules (closed comedones) or grey–white papules (open comedones), which are due to complete or partial ductal occlusion, respec­ tively (...) @bellnet.ca CMAJ 2015. DOI:10.1503 /cmaj.140665 • Acne is common and burdensome, with potential for adverse psychosocial impact and physical sequelae. • This evidence-based guideline was developed to facilitate efficient diagnosis and effective treatment of acne vulgaris in the Canadian population. • Management recommendations are provided for three acne categories: comedonal, mild-to-moderate papulopustular and severe inflammatory acne. • With early diagnosis, treatment of active lesions and prevention

2015 CPG Infobase

154. Efficacy of mupirocin and rifampin used with standard treatment in the management of acne vulgaris. (Abstract)

Efficacy of mupirocin and rifampin used with standard treatment in the management of acne vulgaris. The multiple etiologic factors involved in acne make the use of various medications necessary to treat the condition. This study aimed to determine the efficacy of mupirocin and rifampin used with standard treatment in the management of acne vulgaris. In a multicentre, randomized controlled, triple-blinded study, a total of 105 acne patients, with a clinical diagnosis of moderate to severe acne (...) with standard treatment in the management of acne vulgaris, although none of the treatments had superior efficacy compared with the others.

2013 Iranian journal of pharmaceutical research : IJPR Controlled trial quality: uncertain

155. Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01929057 Recruitment Status : Completed First Posted : August 27, 2013 Last Update

2013 Clinical Trials

156. Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris

Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01931774 Recruitment Status : Completed First Posted : August 29, 2013 Last Update Posted : August 29, 2013

2013 Clinical Trials

157. Severe Acne Vulgaris Management

Severe Acne Vulgaris Management Severe Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Severe Acne Vulgaris (...) Management Severe Acne Vulgaris Management Aka: Severe Acne Vulgaris Management , Cystic Acne From Related Chapters II. Indications Moderate to severe Nodular, pustular, or cystic III. Management: Step 1 - Incorporate Moderate Acne Vulgaris Management See Continue Continue (e.g. ) Continue topical antibiotic (e.g. T) May combine with (e.g. ) Consider IV. Management: Step 2 - Start Oral Antibiotics ral Do not anticipate an effect for 6 to 8 weeks Continue antibiotic for minimum of 6 months should be used

2015 FP Notebook

158. Moderate Acne Vulgaris Management

Moderate Acne Vulgaris Management Moderate Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Moderate Acne (...) Vulgaris Management Moderate Acne Vulgaris Management Aka: Moderate Acne Vulgaris Management , Acne Vulgaris Pharmacologic Management From Related Chapters II. Indication Mild to moderate Inflammatory Comedonal III. Management: Step 1 - OTC topical medications (Self-directed treatment) Approach Patient typically presents already using Most providers start at step 2 Indications Comedones Preparations wash (e.g. Cetaphil) daily Topical 2.5% gel in morning 2.5% is as effective as 5-10% Lower strength

2015 FP Notebook

159. Adjunctive Acne Vulgaris Management

Adjunctive Acne Vulgaris Management Adjunctive Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Adjunctive (...) Acne Vulgaris Management Adjunctive Acne Vulgaris Management Aka: Adjunctive Acne Vulgaris Management From Related Chapters II. Management: Options for women Change if already taking one Increase (50ug minimum) Decrease to low androgenic with low androgenic Norlutin Aygestin Demulen Zovia Indications: Women with androgen hypersecretion increased -S increased Dose: 50 to 200 mg orally daily III. Management: Inflammatory Acne Visible decreases inflammatory acne s Moderate to high potency agents

2015 FP Notebook

160. Acne Vulgaris Management

Acne Vulgaris Management Acne Vulgaris Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Acne Vulgaris Management Acne (...) Vulgaris Management Aka: Acne Vulgaris Management , Acne Vulgaris Non-Pharmacologic Management From Related Chapters II. Management: Exacerbating factors to avoid Medications that exacerbate acne Androgenic steroids (e.g. , Testosterone s s ( ) Environment Hot Greasy (fast-food kitchen, garage) Oil based Cosmetics Cosmetics with Lanolin or petroleum jelly Oil based s or s Emotional Stress Physical Pressure (acne mechanica) Tight chinstrap Helmet III. Management: Myths (non-causes of Acne Vulgaris

2015 FP Notebook

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>